DELTYBA

This brand name is authorized in Austria, Croatia, Estonia, France, Hong Kong SAR China, Ireland, Japan, Lithuania, Poland, Romania, South Africa, Spain, Turkey, UK.

Active ingredients

The drug DELTYBA contains one active pharmaceutical ingredient (API):

1	Delamanid UNII 8OOT6M1PC7 - DELAMANID
	The pharmacological mode of action of delamanid involves inhibition of the synthesis of the mycobacterial cell wall components, methoxy-mycolic and keto-mycolic acid. The identified metabolites of delamanid do not show anti-mycobacterial activity.
	Read more about Delamanid

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DELTYBA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
DELTYBA Dispersible tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J04AK06		J Antiinfectives for systemic use → J04 Antimycobacterials → J04A Drugs for treatment of tuberculosis → J04AK Other drugs for treatment of tuberculosis
Discover more medicines within J04AK06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1646906, 1646917, 1646928, 1683424, 1862524
ES	Centro de información online de medicamentos de la AEMPS	113875004
FR	Base de données publique des médicaments	64639797
GB	Medicines & Healthcare Products Regulatory Agency	286220
HK	Department of Health Drug Office	64412
JP	医薬品医療機器総合機構	6222006F1029
LT	Valstybinė vaistų kontrolės tarnyba	1075162, 1093371
PL	Rejestru Produktów Leczniczych	100323243
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63026001
TR	İlaç ve Tıbbi Cihaz Kurumu	8680683090011
ZA	Health Products Regulatory Authority	52/20.2.3/0460